If a single agent is tolerated that agent may be continued. This trial will be conducted using a Simon two- stage phase II trial design in which 8 evaluable participants will enroll and if 3 or more of the 8 have an objective response, then accrual would continue until a total of 20 evaluable participants have been treated. If there are 9 or more of 20 (45.0%) who experience a response, this would be sufficiently interesting to warrant further study. In the event that a participant develops a response (>30% decrease in target lesions as compared with baseline scan) following initial progression or “pseudo-progression” , this response will be considered as an objective response in the determination to expand accrual . 39 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 3.2 DRUG ADMINISTRATION General Rule: A window of +/ - 14 days for a scheduled treatment is allowed in the event of scheduling issues (i.e., holiday, bad weather or other scheduling issues). The minimum time between administrations of a similar agent is 11 days. Where feasible PDS0101 should be administered first, followed by NHS -IL12 (when given), followed by M7824. 3.2.1 PDS0101 PDS0101 will be administered every 4 weeks for 6 doses followed by every three months (i.e. every 12 weeks) for an additional two doses.